1. Japan Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Kringle Pharma, Inc.

Kringle Pharma, Inc.

4884.T
Kringle Pharma, Inc.JP flagTokyo Stock Exchange
352.00
JPY
-25.00
- -
2.84BMarket Cap
Kringle Pharma, Inc.
4884.T
(Tokyo Stock Exchange)

Recent

price

352.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
423.44
69.76
80.69
12.85
12.51
10.55
13.58
Revenue per Share
-84.67
-273.52
-106.7
-72.51
-68.33
-158.46
-118.21
-133.92
-157.65
Basic EPS, GAAP
-265.5
-306.8
-132.63
-135.05
3.25
-127.84
-103.32
-110.46
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-322.15
-495.92
-421.51
-60.03
-56
-201.93
-116.44
-235.1
-195.14
Book Value per Share
680.03
195.95
1,981.78
603.37
574.39
375.07
329.44
191.36
404.62
Tangible Book Value per Share
1
1
1
4
5
5
6
7
6
Basic Weighted Avg Shares
- -
- -
468
290
392
69
80
72
78
Sales/Revenue/Turnover
- -
- -
-36.7
-123.51
-108.76
-1,283.41
-1,021.87
-1,259.37
-1,207.01
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-65
-302
-118
-301
-332
-854
-756
-916
-905
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-25.2
-103.94
-84.69
-1,233.43
-945.12
-1,268.79
-1,161.12
Profit Margin (%)
520
218
2,190
2,507
3,045
2,409
2,628
1,946
2,713
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
518
216
2,189
2,506
2,789
2,022
2,108
1,309
2,322
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'23
Dec'24
Mar'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
7
Market Capitalization
4,294
4,316
3,002

Working Capital

FRC

•

in mil. unless spec.
Sep'23
Dec'24
Mar'24
Total Current Assets
2,618
2,844
2,911
Cash, Cash Equivalents & STI
2,136
2,341
2,490
Accounts Receivable, Net
8
25
- -
Inventories
364
364
364
Total Current Liabilities
209
94
198
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-7.07%
-37.9%
Free Cash Flow
- -
-854.41%
14.31%
Net Income, GAAP
- -
66.57%
21.13%
Sales/Revenue/Turnover
- -
-15.87%
-9.77%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
19
24
- -
- -
80
2025
- -
- -
- -
- -
72
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-29.53
- -
- -
- -
-118.21
2025
- -
- -
- -
- -
-133.92
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Aptose Biosciences Inc. (APTO)
Tetra Bio-Pharma Inc. (TBPMF)
Opthea Limited (CKDXF)
Navidea Biopharmaceuticals, Inc. (NAVB)
NanoGroup S.A. (NNG.WA)
Actinium Pharmaceuticals, Inc. (ATNM)
Business
Kringle Pharma, Inc. (TSE: 4884) is a late clinical-stage biopharmaceutical company primarily engaged in the research, development, manufacturing, and marketing of hepatocyte growth factor (HGF)-based regenerative pharmaceuticals for intractable diseases. The company develops recombinant human HGF protein drugs including KP-100IT (oremepermin alfa) for acute spinal cord injury in Phase III with topline data announced in February 2024 and marketing authorization application submitted in November 2024; HGF for vocal fold scar in ongoing Phase III; HGF for amyotrophic lateral sclerosis following Phase II completion; HGF for acute kidney injury post Phase I; and partner Claris Biotherapeutics' program for neurotrophic keratitis in Phase I/II, with additional basic research and joint academic programs targeting idiopathic osteonecrosis of the femoral head, idiopathic pulmonary fibrosis, peripheral neuropathy, chronic spinal cord injury, and combination therapies with iPS cells. Founded on December 21, 2001, and headquartered in Saito Bio Incubator, Ibaraki, Osaka, Japan, with an additional office in Nakanoshima, Osaka, Kringle Pharma operates mainly in Japan while pursuing global partnerships including capital and business alliances with TOHO HOLDINGS CO., LTD. and Maruishi Pharmaceutical Co., Ltd. for Japanese distribution of acute spinal cord injury drugs; a license and supply agreement with Claris Biotherapeutics, Inc. (US) renewed for production scale-up in September 2023; joint research agreements with Keio University School of Medicine since 2021 for spinal cord injury therapies, Kobe University in June 2025 for Peyronie's disease, Gifu University in April 2024 for femoral head necrosis, Kanazawa University in June 2024 for pulmonary fibrosis, and Keio University in November 2024 for spinal cord injury biomarkers; US orphan drug designation and FDA pre-IND meetings in 2023; and patent grants and applications including for nervous disease treatments in Europe and new manufacturing processes.